DAIICHI-SANKYO-EUROPE
8.12.2022 08:01:35 CET | Business Wire | Press release
Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) announced today that the primary endpoint was met in the Phase 3 cardiovascular CLEAR (Cholesterol Lowering via Bempedoic acid, an ATP citrate lyase (ACL)-Inhibiting Regimen) Outcomes Trial, demonstrating statistically significant relative risk reduction in major adverse CV events (MACE-4) in patients treated with 180 mg/day bempedoic acid compared to placebo (with no or very low statin background).1,3
Comprehensive data from the CLEAR Outcomes Trial, led by US-based biotech company Esperion Therapeutics Inc., will be presented at a key medical congress in early 2023 and subsequently submitted to applicable regulatory authorities. The initial findings from the data indicate that bempedoic acid is the first oral, ACL inhibitor known to reduce both LDL-C levels and risk of major adverse CV events.1 The findings are congruent with previous significant evidence and the latest clinical guidelines highlighting that the lower a person’s LDL-C level, the lower their cardiovascular risk.4
“The positive results from the CLEAR Outcomes Trial represents a pivotal step towards reducing the impact of CVD in Europe for patients who are currently at high risk of heart attack and stroke,” said Professor Kausik Ray, Professor of Public Health and President of the European Atherosclerosis Society, Honorary Consultant Cardiologist, Director ICTU Global and Deputy Director of the Imperial Clinical Trials Unit at Imperial College London. “I am very excited to see more data from the trial over the coming months and better understand how bempedoic acid can continue to help clinicians bring LDL-C levels of patients to guideline-recommended goals and thus reduce the impact of cholesterol on CV health in Europe.”
“With 10,000 lives lost everyday to CVD in Europe, we are truly encouraged by this new data, which demonstrates that bempedoic acid does reduce the risk of serious CV events for patients who are at high-risk of experiencing a heart attack or stroke,”1,4 said Dr Stefan Seyfried, Vice President Medical Affairs Specialty Medicines, Daiichi Sankyo Europe GmbH. “We look forward to sharing additional analyses and insights, as well as working closely with the scientific and clinical communities, to better understand how the data can support their care for CVD patients across Europe.”
CLEAR Outcomes was a Phase 3, event-driven, randomised, multicenter, double-blind, placebo-controlled trial designed to evaluate whether treatment with bempedoic acid reduced the risk of CV events in patients with or who are at high risk for ASCVD with documented statin intolerance and elevated LDL-C levels (fasting blood LDL-C ≥ 100 mg/dL (2.6 mmol/L)).3 The study, which was fully enrolled in August 2019, included 14,014 patients at over 1,200 sites in 32 countries. Patients had at least 36 months of follow-up.3
-ENDS-
About bempedoic acid
Bempedoic acid (commercialised in the European Economic Area, Turkey and Switzerland as NILEMDO®▼) is a first-in-class, oral treatment which lowers cholesterol, and which can be combined with other oral treatments to help lower cholesterol even further.2,5 Bempedoic acid inhibits ATP citrate lyase (ACL), an enzyme which is involved in the production of cholesterol in the liver.2
Bempedoic acid has been approved for use in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:2
- in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or
- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.
Bempedoic acid acts on the well-known cholesterol synthesis pathway, upstream of the statin target in the liver, which allows additional LDL-C lowering when added to statin or other lipid-lowering therapies. Due to its unique mechanism of action, bempedoic acid is not activated in skeletal muscle.
Daiichi Sankyo Europe has licensed exclusive commercialisation rights to bempedoic acid in the European Economic Area, Turkey and Switzerland from Esperion and is the full Marketing Authorisation Holder in these territories.
About Daiichi Sankyo
Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose “to contribute to the enrichment of quality of life around the world.” In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realise our 2030 Vision to become an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.”
For more information, please visit www.daiichisankyo.com
▼ This medicinal product is subject to additional monitoring.
____________________________________________________
2 European Medicines Agency. NILEMDO Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/nilemdo-epar-product-information_en.pdf. Last accessed December 2022.
3 Nicholls, S.J., et.al. Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance. Am Heart J. 2021. 235: 104–112.
4 The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). ESC/EAS guidelines for the management of dyslipidaemia. Eur Heart J. 2020. 41(1):111–188.
5 SwissMedic. NILEMDO (bempedoic acid) Product Information for Human Medicinal Products. Available at: https://www.swissmedic.ch/swissmedic/en/home/about-us/publications/public-summary-swiss-par/public-summary-swiss-par-nilemdo.html. Last accessed December 2022.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221207005816/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Type One Energy, Tokamak Energy, and AECOM Form the UK Infinity Fusion Consortium to Accelerate Development of a Commercial Fusion Power Plant in the United Kingdom6.5.2026 10:00:00 CEST | Press release
Type One Energy, Tokamak Energy, and AECOM today announced the UK Infinity Fusion Consortium to pursue development of the first private-sector-led fusion power plant project in the United Kingdom. Together, the companies intend to develop a fusion project that is commercially credible, deployable using existing enabling technologies, and capable of attracting private capital — consistent with the long-term goals of the government’s recently announced UK Fusion Strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260506129586/en/ (From left to right) Warrick Matthews, CEO of Tokamak Energy; Chris Mowry, CEO of Type One Energy; and Troy Rudd, Chairman and CEO of AECOM sign the UK Infinity Fusion Consortium during His Majesty King Charles III’s visit to New York City. This announcement comes at a time of increasing U.S.-U.K. bilateral cooperation on fusion. His Majesty King Charles III said during his address to the United
59% of Organizations Made a "Bad AI Hire" in the Past Year, New TestGorilla Research Reveals6.5.2026 10:00:00 CEST | Press release
Study of nearly 2,000 senior hiring leaders finds 53% now prioritize AI fluency over domain expertise, but a critical gap between definitions and measurement is producing confident wrong hires on both sides of the Atlantic TestGorilla, the leading skills-based hiring platform, today released The State of Hiring for AI Fluency, revealing a fundamental shift in talent evaluation: AI fluency has overtaken domain expertise as the top hiring priority. 53% of hiring managers now prefer candidates with strong AI fluency over deep subject matter experts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260506155219/en/ TestGorilla's The State of Hiring for AI Fluency Report Reveals a Transatlantic Divide between US and UK: Study of nearly 2,000 senior hiring leaders finds 53% now prioritize AI fluency over domain expertise, but a critical gap between definitions and measurement is producing confident wrong hires on both sides of the A
Pure Energie Selects Kraken to Manage Wind, Solar and Storage6.5.2026 09:00:00 CEST | Press release
Kraken operating system to manage Pure Energie’s growing portfolio on one intelligent platformPure Energie to benefit from seamless co-ordination across customer load, wind, solar and batteries – maximizing asset value while helping to balance the grid20 sites to onboard in H1 2026, with further expansion planned Pure Energie, a Dutch clean energy company, has selected Kraken – the AI-powered operating system transforming global utilities – to manage and optimize its consumer, wind, solar and battery portfolio across the Netherlands. Kraken brings together grid-scale assets and consumer demand on the same platform, co-ordinating them as a single, intelligent portfolio. This enables Pure Energie to optimize demand and generation in real time – maximizing asset value and helping reduce imbalance costs. The partnership will deliver an energy management system which includes retail balancing, day-ahead curtailment, intraday trading, imbalance optimization, and ancillary market access, alon
Thredd and Currensea Expand Strategic Partnership to Power Next Phase of Growth6.5.2026 09:00:00 CEST | Press release
Four-year renewal builds on long-standing collaboration supporting the payments technology platform behind co-branded reward-earning debit cards and the UK’s top-rated travel spending card Thredd, the AI-first issuer processing platform, today announced the renewal and extension of its longstanding partnership with Currensea, the market-leading payments technology platform. The new agreement extends the relationship for an additional four years, reinforcing a collaboration that has been in place since 2019. Currensea has built a strong reputation among travellers with its multi-bank travel card that links directly to customers’ existing bank accounts, offering competitive FX rates without the need to preload funds. In recent years, Currensea has expanded its offering through co-brand partnerships with leading global travel and hospitality brands, including Hilton Hotels, Marriott Bonvoy and United Airlines, allowing cardholders to earn competitive rewards on their day-to-day debit spen
AMINA Becomes First Bank to Support Canton Coin Trading and Custody6.5.2026 08:30:00 CEST | Press release
Swiss-regulated AMINA provides clients with regulated access to the network that DTCC, Visa, BitGo, and others are building on AMINA Bank AG ("AMINA"), a Swiss Financial Market Supervisory Authority (FINMA)-regulated crypto bank with global reach, today becomes the first bank to support Canton Coin (CC), the native token of Canton Network, offering custody and trading services to its clients. Canton Network is a public, privacy-preserving blockchain built for capital markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260505860056/en/ AMINA Becomes First Bank to Support Canton Coin Trading and Custody Canton has gained significant institutional momentum in recent months, attracting TradFi and DeFi organizations, including the DTCC, Visa, and BitGo, that are building next-generation settlement, tokenisation, custody, and collateral workflows on the network. Canton is also developing an on-chain capital markets ecosystem t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom